{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:17:16Z","timestamp":1762867036171,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,1,24]],"date-time":"2017-01-24T00:00:00Z","timestamp":1485216000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Novartis Pharma KK"},{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corp","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010793","name":"Pfizer Japan","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010793","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Research funding from Japan Heart Foundation and the Naito Foundation"},{"name":"Dainippon-Sumitomo Pharmaceutical Company"},{"name":"Research funding from Nara Red Cross Blood Distributing Center"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s13730-016-0245-y","type":"journal-article","created":{"date-parts":[[2017,1,24]],"date-time":"2017-01-24T06:36:41Z","timestamp":1485239801000},"page":"61-65","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Acute pulmonary thromboembolism occurring during treatment with tolvaptan in a patient with autosomal-dominant polycystic kidney disease"],"prefix":"10.1007","volume":"6","author":[{"given":"Katsuhiko","family":"Morimoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Akai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Yano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miho","family":"Tagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-ichi","family":"Samejima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiko","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,24]]},"reference":[{"key":"245_CR1","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1159\/000045214","volume":"80","author":"E Higashihara","year":"1998","unstructured":"Higashihara E, Nutahara K, Kojima M, Tamakoshi A, Yoshiyuki O, Sakai H, et al. Prevalence and renal prognosis of diagnosed autosomal dominant polycystic kidney disease in Japan. Nephron. 1998;80:421\u20137.","journal-title":"Nephron"},{"key":"245_CR2","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","volume":"9","author":"VH Gattone 2nd","year":"2003","unstructured":"Gattone VH 2nd, Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med. 2003;9:1323\u20136.","journal-title":"Nat Med"},{"key":"245_CR3","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407\u201318.","journal-title":"N Engl J Med"},{"key":"245_CR4","first-page":"25","volume":"2","author":"M Yasaka","year":"1993","unstructured":"Yasaka M, Beppu S. Hypercoagulability in the left atrium: Part II: Coagulation factors. J Heart Valve Dis. 1993;2:25\u201334. discussion 35\u20136.","journal-title":"J Heart Valve Dis"},{"key":"245_CR5","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/0006-355X(95)00030-D","volume":"32","author":"S Kawakami","year":"1995","unstructured":"Kawakami S, Kaibara M, Kawamoto Y, Yamanaka K. Rheological approach to the analysis of blood coagulation in endothelial cell-coated tubes: activation of the intrinsic reaction on the erythrocyte surface. Biorheology. 1995;32:521\u201336.","journal-title":"Biorheology"},{"key":"245_CR6","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/00001721-200209000-00003","volume":"13","author":"H Iwata","year":"2002","unstructured":"Iwata H, Kaibara M. Activation of factor IX by erythrocyte membranes causes intrinsic coagulation. Blood coagulation and fibrinolysis. Blood Coagul Fibrinolysis. 2002;13:489\u201396.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"245_CR7","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.2215\/CJN.00250112","volume":"7","author":"G Kumar","year":"2012","unstructured":"Kumar G, Sakhuja A, Taneja A, Majumdar T, Patel J, Whittle J, et al. Pulmonary embolism in patients with CKD and ESRD. Clin J Am Soc Nephrol. 2012;7:1584\u201390.","journal-title":"Clin J Am Soc Nephrol"},{"key":"245_CR8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1161\/01.CIR.0000042700.48769.59","volume":"107","author":"MG Shlipak","year":"2003","unstructured":"Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation. 2003;107:87\u201392.","journal-title":"Circulation"},{"key":"245_CR9","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1161\/01.HYP.0000137380.91476.fb","volume":"44","author":"T Hrafnkelsdottir","year":"2004","unstructured":"Hrafnkelsdottir T, Ottosson P, Gudnason T, Samuelsson O, Jern S. Impaired endothelial release of tissue-type plasminogen activator in patients with chronic kidney disease and hypertension. Hypertension. 2004;44:300\u20134.","journal-title":"Hypertension"},{"key":"245_CR10","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.2169\/internalmedicine.49.3748","volume":"49","author":"T Maeda","year":"2010","unstructured":"Maeda T, Uchida Y, Oyamada K, Nakajima F. Thrombosis in inferior vena cava due to enlarged renal cysts in autosomal dominant polycystic kidney disease. Intern Med (Tokyo. Japan). 2010;49:1891\u20134.","journal-title":"Intern Med (Tokyo. Japan)"},{"key":"245_CR11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1172\/JCI9516","volume":"106","author":"JE Kaufmann","year":"2000","unstructured":"Kaufmann JE, Oksche A, Wollheim CB, Gunther G, Rosenthal W, Vischer UM. Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Invest. 2000;106:107\u201316.","journal-title":"J Clin Invest"},{"issue":"Suppl 1","key":"245_CR12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2516.2007.01610.x","volume":"14","author":"AB Federici","year":"2008","unstructured":"Federici AB. The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977\u20132007). Haemophilia. 2008;14(Suppl 1):5\u201314.","journal-title":"Haemophilia"},{"key":"245_CR13","doi-asserted-by":"crossref","first-page":"563","DOI":"10.7326\/0003-4819-114-7-563","volume":"114","author":"EH Rose","year":"1991","unstructured":"Rose EH, Aledort LM. Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease. Ann Intern Med. 1991;114:563\u20138.","journal-title":"Ann Intern Med"},{"key":"245_CR14","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1182\/blood-2011-04-347328","volume":"118","author":"JD Blumenfeld","year":"2011","unstructured":"Blumenfeld JD, Tepler J, Mauer A, Coller B, Bichet DG, Smith B. Tolvaptan inhibition of desmopressin effects on coagulation factors in a patient with decreased von Willebrand factor and polycystic kidney disease. Blood. 2011;118:474\u20136.","journal-title":"Blood"},{"issue":"12","key":"245_CR15","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.3748\/wjg.v22.i12.3363","volume":"22","author":"C Chen","year":"2016","unstructured":"Chen C, Chen RP, Lin HH, Zhang WY, Huang XL, Huang ZM. Tolvaptan regulates aquaporin-2 and fecal water in cirrhotic rats with ascites. World J Gastroenterol. 2016;22(12):3363\u201371.","journal-title":"World J Gastroenterol"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13730-016-0245-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-016-0245-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-016-0245-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T00:58:16Z","timestamp":1719017896000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13730-016-0245-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,24]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["245"],"URL":"https:\/\/doi.org\/10.1007\/s13730-016-0245-y","relation":{},"ISSN":["2192-4449"],"issn-type":[{"type":"electronic","value":"2192-4449"}],"subject":[],"published":{"date-parts":[[2017,1,24]]}}}